GLP-1 News — Week of September 28, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
FDA revises GLP-1 import alert to target illegal or poor-quality semaglutide and tirzepatide ingredients
FDA updated Import Alert 66-80 to tighten oversight of imported active pharmaceutical ingredients used in GLP-1 drugs such as semaglutide and tirzepatide. The revision expresses concern about unapproved GLP-1 drug products, including compounded versions for weight loss, and authorizes field staff to detain certain GLP-1 ingredients without physical examination when they come from manufacturers that do not meet FDA standards. This step is part of a broader effort to reduce counterfeit or substandard GLP-1 products in the U.S. market. (2026-09-23)
What this means for you: If you rely on compounded semaglutide or tirzepatide, especially via mail-order or telehealth services, you may see more back orders, sudden discontinuations, or pharmacy switches as ingredient shipments are delayed or blocked. The upside is better protection against contaminated or fake products, but you should have a backup plan with your prescriber, ideally including a path to an FDA-approved pen if you can afford or insure it.
Source: FDA
Related on Metabolic Ledger: /regulatory/where-to-get-compounded-glp1-2026
FDA details safety concerns with unapproved and compounded GLP-1 drugs, highlighting dosing errors and fraudulent products
FDA's drug safety explainer on unapproved GLP-1 drugs reinforces that compounded semaglutide and tirzepatide do not undergo the same pre-market review as approved products and can carry higher risks. As of May 31, 2026, the agency had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, including hospitalizations, dosing mistakes, variable drug concentrations, and use of semaglutide salt forms that differ from the approved active ingredient. FDA also describes fraudulent products that misuse pharmacy names on labels, making it harder for patients to know what they are actually injecting. (2026-09-01)
What this means for you: If you are using a compounded GLP-1, especially a vial you draw up yourself, you should confirm that your pharmacy is properly licensed, that your prescriber knows and trusts it, and that you understand your dosing instructions clearly. If your insurance can cover an approved pen like Ozempic, Wegovy, Mounjaro, or Zepbound, this is a strong prompt to discuss switching to improve dosing accuracy and oversight.
Source: FDA
Related on Metabolic Ledger: /drugs/compounded-vs-brand-glp1
FDA warning letter to Empower Pharmacy over compounded semaglutide and tirzepatide underscores enforcement risks
Reporting on FDA's September 22, 2026 warning letter to Empower Pharmacy states that the agency believes several of Empower's compounded semaglutide and tirzepatide products appear to be copies of FDA-approved drugs rather than truly individualized compounds. The letter reportedly also cites insanitary conditions for sterile production, which could increase infection and product quality risks. This action fits into a wider pattern of FDA stepping up enforcement on large compounders making GLP-1 drugs now that official shortage declarations have ended. (2026-09-22)
What this means for you: If you get compounded GLP-1 from Empower or similar high-volume compounders, you could face tighter eligibility rules, formula changes, higher prices, or abrupt pauses in service as they respond to FDA. You should talk with your prescriber now about alternatives, including switching to an FDA-approved product or to a pharmacy with a clearer regulatory track record, so you are not left without medication if your current source stops shipping.
Source: BariatricPal
Related on Metabolic Ledger: /regulatory/fda-glp1-warning-letters-explained
Novo Nordisk acquires global rights to Hengrui's investigational oral obesity pill outside China
Novo Nordisk agreed to pay up to 2.26 billion euros for global rights, outside China, to an experimental oral obesity drug from Chinese company Hengrui. The deal is part of Novo Nordisk's strategy to expand its obesity pipeline beyond injectable semaglutide and invest heavily in next-generation oral treatments that could complement or eventually compete with its current GLP-1 offerings. Details on the drug's exact mechanism and trial stage were not the focus of the business coverage, but the scale of the investment signals high expectations. (2026-09-29)
What this means for you: This acquisition does not change your treatment options now, but it increases the chances that more non-injectable obesity drugs will reach U.S. patients in the coming years. If weekly injections are a barrier for you, it is worth watching Novo Nordisk's oral pipeline as future pills could offer similar weight loss with a simpler daily routine, though pricing and insurance coverage will be key unknowns.
Source: Cinco Días / El País
Related on Metabolic Ledger: /drugs/orforglipron-vs-semaglutide